Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

PURPOSE: To investigate whether anti–vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor–positive metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with hormone receptor–pos...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Dickler, Maura N., Barry, William T., Cirrincione, Constance T., Ellis, Matthew J., Moynahan, Mary Ellen, Innocenti, Federico, Hurria, Arti, Rugo, Hope S., Lake, Diana E., Hahn, Olwen, Schneider, Bryan P., Tripathy, Debasish, Carey, Lisa A., Winer, Eric P., Hudis, Clifford A.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2016
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5012690/
https://ncbi.nlm.nih.gov/pubmed/27138575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.66.1595
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker